Individualised neoantigen cancer vaccine therapy
- PMID: 38246193
- DOI: 10.1016/S0140-6736(23)02463-7
Individualised neoantigen cancer vaccine therapy
Conflict of interest statement
TS is an advisory board member for Immunocore and Castle Biosciences and is a member of the Medical Oncology Steering Committee in the Collaborative Ocular Oncology Group, all of which are unrelated to the topic of this Comment. MT declares no competing interests.
Comment on
-
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical